Locations:
Search IconSearch
July 27, 2016/Cancer/Research

What’s Best for DCIS?

Review assesses current data regarding treatment options

mammography_650x450

As the use of screening mammography continues to rise, so too does the diagnosis of ductal carcinoma in situ (DCIS), spurring an ongoing debate about how to appropriately manage this condition.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Shah_150x180

Traditionally, active treatment similar to that for early-stage breast cancer has been the standard of care, with options ranging from mastectomy to breast conservation surgery (including radiotherapy), with or without subsequent long-term endocrine therapy.

Lately, data from large observational studies have raised the question of whether the current DCIS treatment paradigm is overly aggressive, and whether a more conservative approach employing observation or endocrine therapy alone is justified.

In a review written for JAMA Oncology, Cleveland Clinic Cancer Center radiation oncologist Chirag Shah, MD, and colleagues summarize the current state of data regarding DCIS treatment options and provide perspective on whether conservative strategies are valid in selected low-risk patients.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024/Cancer/Research
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024/Cancer/Research
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023/Cancer/Research
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad